These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 26320181)

  • 1. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.
    Artemov A; Aliper A; Korzinkin M; Lezhnina K; Jellen L; Zhukov N; Roumiantsev S; Gaifullin N; Zhavoronkov A; Borisov N; Buzdin A
    Oncotarget; 2015 Oct; 6(30):29347-56. PubMed ID: 26320181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.
    Jiang X; Pissaloux D; De La Fouchardiere C; Desseigne F; Wang Q; Attignon V; Fondrevelle ME; De La Fouchardiere A; Perol M; Cassier P; Seigne C; Perol D; Ray-Coquard I; Meeus P; Fayette J; Flechon A; Le Cesne A; Penel N; Tredan O; Blay JY
    Oncotarget; 2015 Sep; 6(28):26388-99. PubMed ID: 26317543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathway activation - New type of biomarkers for tumor morphology and personalized selection of target drugs.
    Buzdin A; Sorokin M; Garazha A; Sekacheva M; Kim E; Zhukov N; Wang Y; Li X; Kar S; Hartmann C; Samii A; Giese A; Borisov N
    Semin Cancer Biol; 2018 Dec; 53():110-124. PubMed ID: 29935311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.
    Giordani E; Zoratto F; Strudel M; Papa A; Rossi L; Minozzi M; Caruso D; Zaccarelli E; Verrico M; Tomao S
    Curr Cancer Drug Targets; 2016; 16(2):175-85. PubMed ID: 26278713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data.
    Tkachev V; Sorokin M; Garazha A; Borisov N; Buzdin A
    Methods Mol Biol; 2020; 2063():235-255. PubMed ID: 31667774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
    Andersen JN; Sathyanarayanan S; Di Bacco A; Chi A; Zhang T; Chen AH; Dolinski B; Kraus M; Roberts B; Arthur W; Klinghoffer RA; Gargano D; Li L; Feldman I; Lynch B; Rush J; Hendrickson RC; Blume-Jensen P; Paweletz CP
    Sci Transl Med; 2010 Aug; 2(43):43ra55. PubMed ID: 20686178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
    Sakle NS; More SA; Dhawale SA; Mokale SN
    Curr Drug Discov Technol; 2020; 17(5):585-615. PubMed ID: 31393251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MKK3 as oncotarget.
    Bossi G
    Aging (Albany NY); 2016 Jan; 8(1):1-2. PubMed ID: 26805700
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies in functional proteomics: Unveiling the pathways to precision oncology.
    Favicchio R; Thepaut C; Zhang H; Arends R; Stebbing J; Giamas G
    Cancer Lett; 2016 Nov; 382(1):86-94. PubMed ID: 26850375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
    Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A
    Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
    Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
    Joo MK; Park JJ; Chun HJ
    World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Pathway Analysis of Mutation Data for Biomarkers Discovery and Scoring of Target Cancer Drugs.
    Zolotovskaia M; Sorokin M; Garazha A; Borisov N; Buzdin A
    Methods Mol Biol; 2020; 2063():207-234. PubMed ID: 31667773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning.
    Miao R; Chen HH; Dang Q; Xia LY; Yang ZY; He MF; Hao ZF; Liang Y
    Pharmacol Res; 2020 Sep; 159():104932. PubMed ID: 32473309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized oncology in interventional radiology.
    Abi-Jaoudeh N; Duffy AG; Greten TF; Kohn EC; Clark TW; Wood BJ
    J Vasc Interv Radiol; 2013 Aug; 24(8):1083-92; quiz 1093. PubMed ID: 23885909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.